The hepatitis C virus (HCV) is the leading cause of liver cancer in the Western Hemisphere. Over 170 million people are infected with this virus and thus at increased risk of liver damage and cancer. HCV infection is curable, and thus such health consequences are completely avoidable. However the current HCV therapy is inadequate, as it is associated with severe side effects and only effective in about half of treate individuals. Effective HCV treatment will require antivirals targeting multiple HCV replication steps that can be used in combination to avoid the derivation of resistant viruses. The HCV cell entry process is an attractive target for antiviral development. Inhibiting this stage of the virallife cycle would curtail the persistence of HCV in vivo, which requires constant infection of new cells, as well as the spread of viral mutants that have developed resistance to other HCV inhibitors. The research proposed in this application will advance our understanding of HCV cell entry mechanisms, with the ultimate goal of uncovering novel antiviral targets. Although we now know that numerous host factors are required for HCV cell entry, we do not understand how they mediate HCV infection. The experiments described in this application are based on the hypothesis that the incoming HCV virion utilizes each of these cellular factors in a sequential manner to mediate cell entry. As two of the host proteins that are required for HCV cell entry are tight junction proteins, it is likely that cell polarity, which regulates the localization and funcions of these proteins, impacts the HCV cell entry process. Although the majority of HCV cell entry studies have been conducted in non-polarized cells, we have recently developed the first polarized cell system that permits efficient infection of authentic HCV grown in cell culture. This system will serve as the foundation for the studies proposed in this application. Specifically, we propose experiments to compare HCV cell entry pathways in non-polarized and polarized using a variety of HCV cell entry factor specific inhibitors. Furthermore, we will test how modulating cell polarity influences HCV cell entry, and examine the host factor requirements with entry factor specific inhibitors, silencing, and complementation with a variety of mutants. We will also analyze when and where each entry factor is used by analyzing the kinetics of action of entry factor specific inhibitors and visualizing the HCV cell entry process in non-polarized and polarized cells. Finally, we will identify physical and genetic interactions between host factors and the incoming HCV virion, and explore how such interactions are affected by cell polarity.

Public Health Relevance

The development of novel, more effective, and better-tolerated therapies targeting the hepatitis C virus (HCV) has been hampered by an incomplete understanding of its basic mechanisms of replication. The experiments in this proposal are aimed at providing an in-depth understanding of how the HCV virion enters a host cell with a focus on how cell polarity regulates this process and how cellular proteins we recently found to be essential for this process, interact with and are utilized by the incoming virion. Such information will be directly relevant to the development of HCV antivirals and small animal models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK095125-02
Application #
8523846
Study Section
Virology - A Study Section (VIRA)
Program Officer
Doo, Edward
Project Start
2012-08-15
Project End
2017-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
2
Fiscal Year
2013
Total Cost
$352,557
Indirect Cost
$142,669
Name
Icahn School of Medicine at Mount Sinai
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Chambers, Matthew T; Schwarz, Megan C; Sourisseau, Marion et al. (2018) Probing Zika Virus Neutralization Determinants with Glycoprotein Mutants Bearing Linear Epitope Insertions. J Virol 92:
Mitchell, Jonathan K; Midkiff, Bentley R; Israelow, Benjamin et al. (2017) Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R. MBio 8:
Fulton, Benjamin O; Sachs, David; Schwarz, Megan C et al. (2017) Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion. J Virol 91:
Hopcraft, Sharon E; Evans, Matthew J (2016) Liver capsule: Hepatitis C virus host cell entry. Hepatology 63:1013
Hopcraft, Sharon E; Azarm, Kristopher D; Israelow, Benjamin et al. (2016) Viral Determinants of miR-122-Independent Hepatitis C Virus Replication. mSphere 1:
Schwarz, Megan C; Sourisseau, Marion; Espino, Michael M et al. (2016) Rescue of the 1947 Zika Virus Prototype Strain with a Cytomegalovirus Promoter-Driven cDNA Clone. mSphere 1:
Zuiani, Adam; Chen, Kevin; Schwarz, Megan C et al. (2016) A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. J Virol 90:10499-10512
Hopcraft, Sharon E; Evans, Matthew J (2015) Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. Hepatology 62:1059-69
Israelow, Benjamin; Narbus, Christopher M; Sourisseau, Marion et al. (2014) HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology 60:1170-9
Israelow, Benjamin; Mullokandov, Gavriel; Agudo, Judith et al. (2014) Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. Nat Commun 5:5408

Showing the most recent 10 out of 18 publications